Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

IGM BIOSCIENCES, INC. — Lobbying — Receipts Report

LD-2 disclosure · 3rd Quarter - Report

IGM BIOSCIENCES, INC.

via STRATEGIC MARKETING INNOVATIONS

3rd Quarter (July 1 - Sep 30) · 2023Posted Oct 19, 2023Filing document ↗LDA record ↗

Income$10Kfee reported

Client

Name: IGM BIOSCIENCES, INC.
Description: Development of engineered IgM antibodies
Location: California · United States of America

Registrant

Firm: STRATEGIC MARKETING INNOVATIONS
Description: Federal relations firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Defense
Antibody therapies
LobbyistsWILLIAM MCCANN · mr EVAN DORNER
Covered position (WILLIAM MCCANN): Chief of Staff, Legislative Director, Rep. Marty Meehan
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.